Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity (NCT02798679) | Clinical Trial Compass
CompletedNot Applicable
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
United States40 participantsStarted 2016-08
Plain-language summary
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
Who can participate
Age range45 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Stage I-III breast cancer or lymphoma with a \>2 year life expectancy
* A treatment plan that includes anthracyclines and/or trastuzumab
* Age \>45 years
* Able to hold breath for 10 seconds
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Exclusion Criteria:
* Refusal or inability to provide informed consent
* Known heart failure or LVEF \<50%
* Heart rate over 100 bpm
* Renal dysfunction with GFR \<30 mL/min/1.73m2
* Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices
* Symptomatic claustrophobia
* Plans to move within 24 months of enrollment
What they're measuring
1
Cardiotoxicity assessed clinically or by cardiac MRI